Exploring the emerging role of CRISPR-Cas systems in probiotic development

Abstract

Modification of the gut microbiota by beneficial microbes can enhance an organism’s lifespan, giving rise to the concept of probiotics. Probiotics are live microorganisms that provide health benefits when taken in sufficient amounts. Owing to their outstanding health benefits, probiotics have experienced rapid expansion and gained interest for the development of new applications. The exploration of microbial applications via genetic modification is currently of great interest to researchers. Genetic engineering using the clustered regularly interspaced short palindromic repeat (CRISPR)-Cas system has received considerable attention and has established applications. Owing to these enhanced properties, the CRISPR-Cas system is currently used in medicine, agriculture, food, and biotechnology. Considering the adaptive immune system in bacteria, this genetic tool is used to alter the microbial genome. Lactic acid bacteria (LAB) are widely recognized for their probiotic potential, and over 40% of LAB species contain the CRISPR-Cas system. The rising demand for probiotics and their expanding applications necessitate the enhancement of their existing characteristics. The CRISPR-Cas system, recognized for its precision, accuracy, and speed, has enabled researchers to modify the genomes of probiotics, thereby enhancing their beneficial attributes. This system can enhance probiotic properties through additive, subtractive, or modulatory mechanisms. Various approaches have been developed to improve probiotic functionalities using the CRISPR-Cas system, such as substituting slow promoters with efficient alternatives, eliminating undesirable components, boosting metabolism, and increasing tolerance levels. Furthermore, CRISPR-engineered probiotics have emerged as next-generation probiotics with enhanced properties and advanced applications across diverse fields, including the food, medicine, agriculture, and pharmaceutical sectors.

Keywords

Probiotics / CRISPR-Cas / CRISPR-based probiotics / Genome editing / Lactic acid bacteria

References

[1] F. Santos—Beneit, What is the role of microbial biotechnology and genetic engineering in medicine, Microbiologyopen 13 (2024) 1-31, doi: 10.1002/mbo3.1406.

[2] H. Li, Y. Yang, W. Hong, M. Huang, M. Wu, X. Zhao, Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects, Signal Transduct Target. 5 (2020), doi: 10.1038/s41392-019-0089-y.

[3] A.N. Ansori, et al., Application of CRISPR—Cas9 genome editing technology in various fields: a review, Narra J. 3 (2023) e184, doi: 10.52225/narra.v3i2.184.

[4] A.K. Sadanov, et al., Engineering useful microbial species for pharmaceutical applications, Microorganisms 13 (2025) 599, doi: 10.3390/microorganisms13030599.

[5] Y. Ishino, M. Krupovic, P. Forterre, History of CRISPR—Cas from encounter with a mysterious, J. Bacteriol. 200 (2018) e00580—17, doi: 10.1128/jb.00580-17.

[6] J. Wei, Y. Li, CRISPR—based gene editing technology and its application in microbial engineering, Eng. Microbiol. 3 (2023) 100101, doi: 10.1016/j.engmic.2023.100101.

[7] M. Bagheri, A. Zahmatkesh, A. Hussain, T. Taj, S. Ashique, N. Mojgani, Gut microbiota: role in health and disease, Role Gut Microbiot. Postbiot. Colorect. Cancer 1 (2025) 1-14, doi: 10.1007/978-3-031-86065-2_1.

[8] A. Mayorga—Ramos, J. Zúñiga—Miranda, S.E. Carrera—Pacheco, C. Barba—Ostria, L.P. Guamán, CRISPR—Cas—based antimicrobials: design, challenges, and bacterial mechanisms of resistance, ACS Infect. Dis. 9 (2023) 1283-1302, doi: 10.1021/acsinfecdis.2c00649.

[9] K. Tavakoli, A. Pour—Aboughadareh, F. Kianersi, P. Poczai, A. Etminan, L. Shooshtari, Applications of CRISPR—Cas9 as an advanced genome editing system in life sciences, BioTech 10 (2021) 14, doi: 10.3390/biotech10030014.

[10] G. Ramachandran, D. Bikard, Editing the microbiome the CRISPR way, Philos. Trans. R. Soc. B Biol. Sci. 374 (2019) 20180103, doi: 10.1098/rstb.2018.0103.

[11] B.A. Tegegne, B. Kebede, Probiotics, their prophylactic and therapeutic applications in human health development: a review of the literature, Heliyon 8 (2022) e09725, doi: 10.1016/j.heliyon.2022.e09725.

[12] K.C. Baral, R. Bajracharya, S.H. Lee, H.K. Han, Advancements in the pharmaceutical applications of probiotics: dosage forms and formulation technology, Int. J. Nanomedicine. 16 (2021) 7535-7556, doi: 10.2147/IJN.S337427.

[13] S. Bhogoju, S. Nahashon, Recent advances in probiotic application in Animal health and nutrition: a review, Agriculture 12 (2022) 304, doi: 10.3390/agriculture12020304.

[14] A. Roberts, R. Barrangou, Applications of CRISPR—Cas systems in lactic acid bacteria, FEMS Microbiol. Rev. 44 (2020) 523-537, doi: 10.1093/femsre/fuaa016.

[15] A.E. Briner, et al., Occurrence and diversity of CRISPR—Cas systems in the genus Bifidobacterium, PLoS One 10 (2015) e0133661, doi: 10.1371/journal.pone.0133661.

[16] L. Liu, S.E. Helal, N. Peng, CRISPR—Cas—based engineering of probiotics, Biodes Res. 5 (2023) 0017, doi: 10.34133/bdr.0017.

[17] J. Ma, et al., Engineered probiotics, Microb. Cell Fact. 21 (2022) 72, doi: 10.1186/s12934-022-01799-0.

[18] K. Mugwanda, et al., Recent advances in genetic tools for engineering probiotic lactic acid bacteria, Biosci. Rep. 43 (2023) 1-27, doi: 10.1042/BSR20211299.

[19] S.F. Mazhar, et al., The prospects for the therapeutic implications of genetically engineered probiotics, J. Food Qual. 2020 (2020) 1-11, doi: 10.1155/2020/9676452.

[20] Y. Mu, et al., Development and applications of CRISPR/Cas9—based genome editing in Lactobacillus, Int. J. Mol. Sci. 23 (2022) 12852, doi: 10.3390/ijms232112852.

[21] A. Hussain, S.A. Ali, Probiotics and immunity: exploring the development of Probiotics concept, EC Pharmacol. Toxicol. 12 (2024) 01-06.

[22] P.A. Mackowiak, Recycling Metchnikoff: probiotics, the intestinal microbiome and the quest for long life, Front. Public Heal. 1 (2013) 1-3, doi: 10.3389/fpubh.2013.00052.

[23] A. Hussain, N. Koser, S.M. Aun, M.F. Siddiqui, S. Malik, S.A. Ali, Deciphering the role of probiotics in mental health: a systematic literature review of psychobiotics, Benef. Microbes. 16 (2024) 135-156, doi: 10.1163/18762891-bja00053.

[24] A. Hussain, N. Mojgani, N. Koser, M.F. Siddiqui, S.A. Ali, Deciphering the anti—aging potential of probiotics: a narrative review on gerobiotics, Microbe 9 (2025) 100607, doi: 10.1016/j.microb.2025.100607.

[25] C. Hill, et al., The International scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic, Nat. Rev. Gastroenterol. Hepatol. 11 (2014) 506-514, doi: 10.1038/nrgastro.2014.66.

[26] G.G. Syngai, R. Gopi, R. Bharali, S. Dey, G.M.A. Lakshmanan, G. Ahmed, Probiotics — the versatile functional food ingredients, J. Food Sci. Technol. 53 (2016) 921-933, doi: 10.1007/s13197-015-2011-0.

[27] B. Sarita, D. Samadhan, M.Z. Hassan, E.G. Kovaleva, A comprehensive review of probiotics and human health—current prospective and applications, Front. Microbiol. 15 (2025) 1-14, doi: 10.3389/fmicb.2024.1487641.

[28] A. Hussain, S.A. Ali, Exploring Enterococcus species for their next—generation probiotics potential, Probiot., Prebiot., Postbiot. Human Health Sustain. Food Syst. 13 (2024), doi: 10.5772/intechopen.1007306.

[29] A. Khoso, et al., Molecular assessments of antimicrobial protein enterocins and quorum sensing genes and their role in virulence of the genus Enterococcus, Probiot. Antimicrob. Prote. 17 (2025) 3144-3155, doi: 10.1007/s12602-024-10278-4.

[30] A. Hussain, S. Akram, D. Ahmad, M. Rehman, A. Ahmed, S.A. Ali, Molecular assessment and validation of the selected enterococcal strains as probiotics, Prob. Antimicrob. Prot. 17 (2023) 378-392, doi: 10.1007/s12602-023-10163-6.

[31] Q. Tian, et al., Evaluating the health risk of probiotic supplements from the perspective of antimicrobial resistance, Microbiol. Spectr. 13 (2025) 1, doi: 10.1128/spectrum.00019-24.

[32] B.S. Sivamaruthi, P. Kesika, C. Chaiyasut, A review on anti—aging properties of probiotics, Int. J. Appl. Pharm. 10 (2018) 23, doi: 10.22159/ijap.2018v10i5.28249.

[33] K. Śliżewska, P. Markowiak—Kopeć, W. Śliżewska, The role of probiotics in cancer prevention, Cancers 13 (2020) 20, doi: 10.3390/cancers13010020.

[34] A. Hussain, N. Mojgani, S.M.A. Shah, N. Kousar, S.A. Ali, The emerging role of probiotics in the management and treatment of diabetic foot ulcer: a comprehensive review, AIMS Microbiol. 11 (2025) 649-678, doi: 10.3934/microbiol.2025027.

[35] S. Binda, et al., Criteria to qualify microorganisms as ‘probiotic’ in foods and dietary supplements, Front. Microbiol. 11 (2020), doi: 10.3389/fmicb.2020.01662.

[36] J.C. Sniffen, L.V. McFarland, C.T. Evans, E.J.C. Goldstein, Choosing an appropriate probiotic product for your patient: an evidence—based practical guide, PLoS One 13 (2018) e0209205, doi: 10.1371/journal.pone.0209205.

[37] J.A. Krumbeck, et al., In vivo selection to identify bacterial strains with enhanced ecological performance in synbiotic applications, Appl. Environ. Microbiol. 81 (2015) 2455-2465, doi: 10.1128/AEM.03903-14.

[38] T.K. Das, S. Pradhan, S. Chakrabarti, K.C. Mondal, K. Ghosh, Current status of probiotic and related health benefits, Appl. Food Res. 2 (2022) 100185, doi: 10.1016/j.afres.2022.100185.

[39] M. Klein, M.E. Sanders, T. Duong, H.A. Young, Probiotics: from bench to market, Ann. N. Y. Acad. Sci. 1212 (2010) 183-192, doi: 10.1111/j.1749-6632.2010.05839.x.

[40] M.E. Abouelela, Y.A. Helmy, Next—generation probiotics as novel therapeutics for improving Human health: current trends and future perspectives, Microorganisms 12 (2024) 430, doi: 10.3390/microorganisms12030430.

[41] M. Cunningham, et al., Shaping the future of probiotics and prebiotics, Trends Microbiol. 29 (2021) 667-685, doi: 10.1016/j.tim.2021.01.003.

[42] M. Abdul Manan, Progress in probiotic science: prospects of functional probiotic—based foods and beverages, Int. J. Food Sci. 2025 (2025) 5567567, doi: 10.1155/ijfo/5567567.

[43] H. Zhang, et al., Next—generation probiotics: microflora intervention to Human diseases, Biomed Res. Int. 2022 (2022) 5633403, doi: 10.1155/2022/5633403.

[44] L. Ortiz—Velez, R. Britton, Genetic tools for the enhancement of probiotic properties, Microbiol. Spectr. 5 (2017) 371-387, doi: 10.1128/microbiolspec.BAD-0018-2016.

[45] A. Tiwari, D.I. Krisnawati, E. Susilowati, C. Mutalik, T.R. Kuo, Next—generation probiotics and chronic diseases: a review of current research and future directions, J. Agric. Food Chem. 72 (2024) 27679-27700, doi: 10.1021/acs.jafc.4c08702.

[46] Z.H. Li, J. Wang, J.P. Xu, J. Wang, X. Yang, Recent advances in CRISPR—based genome editing technology and its applications in cardiovascular research, Mil. Med. Res. 10 (2023) 1-20, doi: 10.1186/s40779-023-00447-x.

[47] P. Yang, et al., Genetic engineering in bacteria, fungi, and oomycetes, taking advantage of CRISPR, DNA 4 (2024) 427-454, doi: 10.3390/dna4040030.

[48] E.S. Lander, The Heroes of CRISPR, Cell 164 (2016) 18-28, doi: 10.1016/j.cell.2015.12.041.

[49] M.A.B. Shabbir, et al., CRISPR—cas system: biological function in microbes and its use to treat antimicrobial resistant pathogens, Ann. Clin. Microbiol. Antimicrob. 18 (2019), doi: 10.1186/s12941-019-0317-x.

[50] K. Saeed, F. Ayub, M.A. Durrani, M. Mujahid, CRISPR Cas systems: from bacterial defense mechanisms to revolutionary tools reshaping genetic research and translation therapeutics, The Microbe. 7 (2025) 100344, doi: 10.1016/j.microb.2025.100344.

[51] Y. Xu, Z. Li, CRISPR—Cas systems: overview, innovations and applications in human disease research and gene therapy, Comput. Struct. Biotechnol. J. 18 (2020) 2401-2415, doi: 10.1016/j.csbj.2020.08.031.

[52] C. Hidalgo—Cantabrana, S. O’Flaherty, R. Barrangou, CRISPR—based engineering of next—generation lactic acid bacteria, Curr. Opin. Microbiol. 37 (2017) 79-87, doi: 10.1016/j.mib.2017.05.015.

[53] A. Parsaeimehr, R.I. Ebirim, G. Ozbay, CRISPR—Cas technology a new era in genomic engineering, Biotechnol. Report. 34 (2022) e00731, doi: 10.1016/j.btre.2022.e00731.

[54] A.H.M. Alduhaidhawi, et al., Prevalence of CRISPR—Cas systems and their possible association with antibiotic resistance in Enterococcus faecalis and Enterococcus faecium collected from Hospital wastewater, Infect. Drug Resist. 15 (2022) 1143-1154, doi: 10.2147/IDR.S358248.

[55] F. Jiang, J.A. Doudna, The structural biology of CRISPR—Cas systems, Curr Opin Struct Biol. 30 (2015) 100-111, doi: 10.1016/j.sbi.2015.02.002.

[56] F. Jiang, J.A. Doudna, CRISPR — Cas9 structures and mechanisms, Annu Rev Biophys. 46 (2017) 505-529, doi: 10.1146/annurev-biophys-062215-010822.

[57] S. Bhatia, Pooja, S.K. Yadav, CRISPR—Cas for genome editing: classification, mechanism, designing and applications, Int. J. Biol. Macromol. 238 (2023) 124054, doi: 10.1016/j.ijbiomac.2023.124054.

[58] Z. Liu, H. Dong, Y. Cui, L. Cong, D. Zhang, Application of different types of CRISPR/Cas—based systems in bacteria, Microb. Cell Fact. 19 (2020) 1-14, doi: 10.1186/s12934-020-01431-z.

[59] M.A. Mengstie, B.Z. Wondimu, Mechanism and applications of crispr/cas—9—mediated genome editing, Biol. Targets Ther. 15 (2021) 353-361, doi: 10.2147/BTT.S326422.

[60] C. Brokowski, M. Adli, CRISPR ethics: moral considerations for applications of a powerful tool, J. Mol. Biol. 431 (2019) 88-101, doi: 10.1016/j.jmb.2018.05.044.

[61] Z.K. Shinwari, F. Tanveer, A.T. Khalil, Ethical issues regarding crispr—mediated genome editing, Curr. Issues Mol. Biol. 26 (2018) 103-110, doi: 10.21775/CIMB.026.103.

[62] J. Li, et al., Establishment of CRISPR—Cas9 system in bifidobacteria animalis AR668, Microb. Cell Fact. 22 (2023) 1-10, doi: 10.1186/s12934-023-02094-2.

[63] M. Zaayman, R.M. Wheatley, Fitness costs of CRISPR—Cas systems in bacteria, Microbiology 168 (2022) 1-10, doi: 10.1099/mic.0.001209.

[64] G. Wang, et al., The diversity of the CRISPR—Cas system and prophages present in the genome reveals the Co—evolution of bifidobacterium pseudocatenulatum and phages, Front. Microbiol. 11 (2020) 1088, doi: 10.3389/fmicb.2020.01088.

[65] A.G. Lindenstrauß, M. Pavlovic, A. Bringmann, J. Behr, M.A. Ehrmann, R.F. Vogel, Comparison of genotypic and phenotypic cluster analyses of virulence determinants and possible role of CRISPR elements towards their incidence in Enterococcus faecalis and Enterococcus faecium, Syst. Appl. Microbiol. 34 (2011) 553-560, doi: 10.1016/j.syapm.2011.05.002.

[66] E. Stout, T. Klaenhammer, R. Barrangou, CRISPR—Cas technologies and applications in food bacteria, Annu. Rev. Food Sci. Technol. 8 (2017) 413-437, doi: 10.1146/annurev-food-072816-024723.

[67] K.L. Palmer, M.S. Gilmore, Multidrug—resistant enterococci lack CRISPR—cas, MBio 1 (2010) e00227-10, doi: 10.1128/mBio.00227-10.

[68] F. Aziz, M.N. Khan, S. Ahmed, S.C. Andrews, Draft genome sequence of Enterococcus faecium SP15, a potential probiotic strain isolated from spring water, BMC Res. Notes. 12 (2019) 10-12, doi: 10.1186/s13104-019-4136-0.

[69] A.B. Crawley, E.D. Henriksen, E. Stout, K. Brandt, R. Barrangou, Characterizing the activity of abundant, diverse, and active CRISPR—Cas systems in lactobacilli, Sci. Rep. 8 (2018) 11544, doi: 10.1038/s41598-018-29746-3.

[70] F. Zuo, H. Marcotte, Advancing mechanistic understanding and bioengineering of probiotic lactobacilli and bifidobacteria by genome editing, Curr. Opin. Biotechnol. 70 (2021) 75-82, doi: 10.1016/j.copbio.2020.12.015.

[71] M. Yadav, P. Shukla, Efficient engineered probiotics using synthetic biology approaches: a review, Biotechnol. Appl. Biochem. 67 (2020) 22-29, doi: 10.1002/bab.1822.

[72] Z. Zhong, et al., Efficient plant genome engineering using a probiotic—sourced CRISPR—Cas9 system, Nat. Commun. 14 (2023) 6102, doi: 10.1038/s41467-023-41802-9.

[73] Z. Xie, Y. Jin, M.J. Miller, Exploiting the endogenous type II—A CRISPR—Cas system for functional engineering of probiotic lacticaseibacillus rhamnosus GG, Microb. Biotechnol. 19 (2026), doi: 10.1111/1751-7915.70303.

[74] L. Yang, et al., Occurrence and diversity of CRISPR loci in Lactobacillus casei group, Front. Microbiol. 11 (2020) 1-9, doi: 10.3389/fmicb.2020.00624.

[75] X. Song, H. Huang, Z. Xiong, L. Ai, S. Yang, CRISPR—Cas9 D10A Nickase—assisted genome editing in Lactobacillus casei, Appl. Environ. Microbiol. 83 (2017), doi: 10.1128/AEM.01259-17.

[76] Y. Xin, T. Guo, Y. Mu, J. Kong, A single—plasmid genome editing system for metabolic engineering of Lactobacillus casei, Front. Microbiol. 9 (2018) 1-11, doi: 10.3389/fmicb.2018.03024.

[77] K. Wiull, L.K. Haugen, V.G.H. Eijsink, G. Mathiesen, CRISPR/Cas9—mediated genomic insertion of functional genes into lactiplantibacillus plantarum WCFS1, Microbiol. Spectr. 13 (2025) 1-16, doi: 10.1128/spectrum.02025-24.

[78] E. Altermann, et al., Complete genome sequence of the probiotic lactic acid bacterium Lactobacillus acidophilus NCFM, Proc. Natl. Acad. Sci. 102 (2005) 3906-3912, doi: 10.1073/pnas.0409188102.

[79] M. Pan, S. O’Flaherty, A. Hibberd, S. Gerdes, W. Morovic, R. Barrangou, The curated Lactobacillus acidophilus NCFM genome provides insights into strain specificity and microevolution, BMC Genom. 26 (2025) 1, doi: 10.1186/s12864-024-11177-2.

[80] J.H. Shin, W.H. Chung, Y.S. Park, Y.D. Nam, Detection and identification of Lactobacillus acidophilus species and its commercial probiotic strains using CRISPR loci—based amplicon analysis, LWT 171 (2022) 114166, doi: 10.1016/j.lwt.2022.114166.

[81] Z. Urshev, D. Ishlimova, Distribution of clustered regularly interspaced palindrome repeats CRISPR2 and CRISPR3 in Lactobacillus delbrueckii ssp. Bulgaricus strains, Biotechnol. Biotechnol. Equip. 29 (2015) 541-546, doi: 10.1080/13102818.2015.1013351.

[82] P. Hao, et al., Complete sequencing and pan—genomic analysis of Lactobacillus delbrueckii subsp. Bulgaricus reveal its genetic basis for industrial yogurt production, PLoS One. 6 (2011) e15964, doi: 10.1371/journal.pone.0015964.

[83] G. Lamothe, L. Jolly, B. Mollet, F. Stingele, Genetic and biochemical characterization of exopolysaccharide biosynthesis by Lactobacillus delbrueckii subsp. Bulgaricus, Arch. Microbiol. 178 (2002) 218-228, doi: 10.1007/s00203-002-0447-x.

[84] H. Huang, X. Song, S. Yang, Development of a RecE/T—assisted CRISPR—Cas9 toolbox for Lactobacillus, Biotechnol. J. 14 (2019) e1800690, doi: 10.1002/biot.201800690.

[85] B. Panahi, M. Majidi, M.A. Hejazi, Genome mining approach reveals the occurrence and diversity pattern of clustered regularly interspaced short palindromic repeats/CRISPR—associated systems in Lactobacillus brevis strains, Front. Microbiol. 13 (2022) 1-12, doi: 10.3389/fmicb.2022.911706.

[86] M. Gueimonde, C. Garrigues, D. van Sinderen, C.G. de los Reyes—Gavilán, A. Margolles, Bile—inducible efflux transporter from bifidobacterium longum NCC2705, conferring Bile resistance, Appl. Environ. Microbiol. 75 (2009) 3153-3160, doi: 10.1128/AEM.00172-09.

[87] F. Zuo, S. Chen, H. Marcotte, Engineer probiotic bifidobacteria for food and biomedical applications — current status and future prospective, Biotechnol. Adv. 45 (2020) 107654, doi: 10.1016/j.biotechadv.2020.107654.

[88] M. Pan, M.A. Nethery, C. Hidalgo—Cantabrana, R. Barrangou, Comprehensive mining and characterization of CRISPR—Cas systems in bifidobacterium, Microorganisms 8 (2020) 720, doi: 10.3390/microorganisms8050720.

[89] X. Han, et al., Characterization of CRISPR—Cas systems in bifidobacterium breve, Microb. Genom.. 8 (2022) 1-12, doi: 10.1099/mgen.0.000812.

[90] X. Han, et al., Harnessing the endogenous type I—C CRISPR—Cas system for genome editing in bifidobacterium breve, Appl. Environ. Microbiol. 90 (2024) e0207423, doi: 10.1128/aem.02074-23.

[91] M. Pan, et al., Genomic and epigenetic landscapes drive CRISPR—based genome editing in Bifidobacterium, Proc. Natl. Acad. Sci. 119 (2022) 1-10, doi: 10.1073/pnas.2205068119.

[92] C. Garrigues, E. Johansen, M.B. Pedersen, Complete genome sequence of bifidobacterium animalis subsp. Lactis BB—12, a widely consumed probiotic strain, J. Bacteriol. 192 (2010) 2467-2468, doi: 10.1128/JB.00109-10.

[93] O. Can, et al., Comparative genomics of Bifidobacterium animalis subsp. Lactis reveals strain—level hyperdiversity, carbohydrate metabolism adaptations, and CRISPR—mediated phage immunity, Fermentation 11 (2025) 179, doi: 10.3390/fermentation11040179.

[94] R. Sapranauskas, G. Gasiunas, C. Fremaux, R. Barrangou, P. Horvath, V. Siksnys, The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli, Nucleic Acid. Res. 39 (2011) 9275-9282, doi: 10.1093/nar/gkr606.

[95] S. Ma, et al., Repurposing endogenous type II CRISPR—Cas9 system for genome editing in Streptococcus thermophilus, Biotechnol. Bioeng. 121 (2024) 749-756, doi: 10.1002/bit.28608.

[96] P. Horvath, et al., Diversity, activity, and evolution of CRISPR loci in Streptococcus thermophilus, J. Bacteriol. 190 (2008) 1401-1412, doi: 10.1128/JB.01415-07.

[97] J.H. Oh, J.P. van Pijkeren, CRISPR—Cas9—assisted recombineering in Lactobacillus reuteri, Nucleic Acids Res. 42 (2014) e131, doi: 10.1093/nar/gku623.

[98] V.J. Price, S.W. McBride, K. Hullahalli, A. Chatterjee, B.A. Duerkop, K.L. Palmer, Enterococcus faecalis CRISPR—Cas is a robust barrier to conjugative antibiotic resistance dissemination in the Murine Intestine, mSphere 4 (2019) e00464, doi: 10.1128/mSphere.00464-19.

[99] P. Gholizadeh, et al., Role of CRISPR—Cas system on antibiotic resistance patterns of Enterococcus faecalis, Ann. Clin. Microbiol. Antimicrob. 20 (2021) 49, doi: 10.1186/s12941-021-00455-6.

[100] A.S. Cabral, et al., CRISPR—Cas systems in enterococci, Brazilian J. Microbiol. 55 (2024) 3945-3957, doi: 10.1007/s42770-024-01549-x.

[101] M. Fang, et al., Engineering probiotic Escherichia coli Nissle 1917 to block transfer of multiple antibiotic resistance genes by exploiting a type I CRISPR—Cas system, Appl. Environ. Microbiol. 90 (2024) e0081124, doi: 10.1128/aem.00811-24.

[102] D. Lee, P. Muir, S. Lundberg, A. Lundholm, L. Sandegren, S. Koskiniemi, A CRISPR—Cas9 system protecting E. coli against acquisition of antibiotic resistance genes, Sci. Rep. 15 (2025) 1545, doi: 10.1038/s41598-025-85334-2.

[103] S. Lin, et al., Oral microto—nano genome—editing system enabling targeted delivery and conditional activation of CRISPR—Cas9 for gene therapy of inflammatory bowel disease, ACS Nano. 18 (2024) 25657-25670, doi: 10.1021/acsnano.4c07750.

[104] K. Neil, et al., High—efficiency delivery of CRISPR—Cas9 by engineered probiotics enables precise microbiome editing, Mol. Syst. Biol. 17 (2021) 1-12, doi: 10.15252/msb.202110335.

[105] N. Ali, C. Vora, A. Mathuria, N. Kataria, I. Mani, Advances in CRISPR—Cas systems for gut microbiome, Prog. Mol. Biol. Transl. Sci. 208 (2024) 59-81, doi: 10.1016/bs.pmbts.2024.07.008.

[106] Ö.K. Ilıkkkan, Analysis of probiotic bacteria genomes: comparison of CRISPR/Cas systems and spacer acquisition diversity, Indian J. Microbiol. 62 (2022) 40-46, doi: 10.1007/s12088-021-00971-1.

[107] M. Pan, R. Barrangou, Combining omics technologies with CRISPR—based genome editing to study food microbes, Curr. Opin. Biotechnol. 61 (2020) 198-208, doi: 10.1016/j.copbio.2019.12.027.

[108] S. Vaid, V.K. Pandey, R. Singh, A.H. Dar, R. Shams, K.S. Thakur, A concise review on development of probiotics from Lactobacillus using CRISPR—Cas technology of gene editing, Food Chem. Adv. 1 (2022) 100099, doi: 10.1016/j.focha.2022.100099.

[109] J. Bonacina, N. Suárez, R. Hormigo, S. Fadda, M. Lechner, L. Saavedra, A genomic view of food—related and probiotic Enterococcus strains, DNA Res. 24 (2017) dsw043, doi: 10.1093/dnares/dsw043.

[110] P. Jarocki, et al., Complete genome sequence of Lactobacillus rhamnosus Pen, a probiotic component of a medicine used in prevention of antibiotic—associated diarrhoea in children, Gut Pathog. 10 (2018) 1-6, doi: 10.1186/s13099-018-0235-z.

[111] C. Castro—López, H.S. García, G.C.G. Martínez—Ávila, A.F. González—Córdova, B. Vallejo—Cordoba, A. Hernández—Mendoza, Genomics—based approaches to identify and predict the health—promoting and safety activities of promising probiotic strains — A probiogenomics review, Trends Food Sci Technol. 108 (2021) 148-163, doi: 10.1016/j.tifs.2020.12.017.

[112] L. Wang, J. Hu, K. Li, Y. Zhao, M. Zhu, Advancements in gene editing technologies for probiotic—enabled disease therapy, iScience 27 (2024) 110791, doi: 10.1016/j.isci.2024.110791.

[113] X. Zhou, et al., Exploiting heterologous and endogenous CRISPR—Cas systems for genome editing in the probiotic Clostridium butyricum, Biotechnol. Bioeng. 118 (2021) 2448-2459, doi: 10.1002/bit.27753.

[114] R. Barrangou, R.A. Notebaart, CRISPR—directed microbiome manipulation across the food supply chain, Trends Microbiol. 27 (2019) 489-496, doi: 10.1016/j.tim.2019.03.006.

[115] Y.J. Goh, R. Barrangou, Harnessing CRISPR—Cas systems for precision engineering of designer probiotic lactobacilli, Curr. Opin. Biotechnol. 56 (2019) 163-171, doi: 10.1016/j.copbio.2018.11.009.

[116] M. Soliman, H.S. Said, M. El—Mowafy, R. Barwa, Novel PCR detection of CRISPR/Cas systems in Pseudomonas aeruginosa and its correlation with antibiotic resistance, Appl. Microbiol. Biotechnol. 106 (2022) 7223-7234, doi: 10.1007/s00253-022-12144-1.

[117] Q. Wang, B. Zhang, X. Xu, F. Long, J. Wang, CRISPR—typing PCR (ct—PCR), a new Cas9—based DNA detection method, Sci. Rep. 8 (2018) 14126, doi: 10.1038/s41598-018-32329-x.

[118] E. Pursey, T. Dimitriu, F.L. Paganelli, E.R. Westra, S. van Houte, CRISPR—Cas is associated with fewer antibiotic resistance genes in bacterial pathogens, Philos. Trans. R. Soc. B Biol. Sci. 377 (2022) 20200464, doi: 10.1098/rstb.2020.0464.

[119] H.S. Kim, J. Kweon, Y. Kim, Recent advances in CRISPR—based functional genomics for the study of disease—associated genetic variants, Exp. Mol. Med. 56 (2024) 861-869, doi: 10.1038/s12276-024-01212-3.

[120] M. Ventura, F. Turroni, D. van Sinderen, Probiogenomics as a tool to obtain genetic insights into adaptation of probiotic bacteria to the human gut, Bioengineered 3 (2012) 73-79, doi: 10.4161/bbug.18540.

[121] J.R. Grant, et al., Proksee: in—depth characterization and visualization of bacterial genomes, Nucl. Acid. Res. 51 (2023) W484-W492, doi: 10.1093/nar/gkad326.

[122] D. Couvin, et al., CRISPRCasFinder, an update of CRISRFinder, includes a portable version, enhanced performance and integrates search for Cas proteins, Nucleic Acids Res. 46 (2018) W246-W251, doi: 10.1093/nar/gky425.

[123] C. Pourcel, et al., CRISPRCasdb a successor of CRISPRdb containing CRISPR arrays and cas genes from complete genome sequences, and tools to download and query lists of repeats and spacers, Nucleic Acids Res. 48 (2019) D535-D544, doi: 10.1093/nar/gkz915.

[124] I. Grissa, G. Vergnaud, C. Pourcel, CRISPRFinder: a web tool to identify clustered regularly interspaced short palindromic repeats, Nucleic Acids Res. 35 (2007) W52-W57, doi: 10.1093/nar/gkm360.

[125] S.S. Abby, B. Néron, H. Ménager, M. Touchon, E.P.C. Rocha, MacSyFinder: a program to mine genomes for molecular systems with an application to CRISPR—Cas systems, PLoS One 9 (2014) e110726, doi: 10.1371/journal.pone.0110726.

[126] J. Russel, R. Pinilla—Redondo, D. Mayo—Muñoz, S.A. Shah, S.J. Sørensen, CRISPRCasTyper: automated identification, annotation, and classification of CRISPR—Cas Loci, Cris. J. 3 (2020) 462-469, doi: 10.1089/crispr.2020.0059.

[127] A. Mitrofanov, O.S. Alkhnbashi, S.A. Shmakov, K.S. Makarova, E.V. Koonin, R. Backofen, CRISPRidentify: identification of CRISPR arrays using machine learning approach, Nucleic Acids Res. 49 (2021) e20, doi: 10.1093/nar/gkaa1158.

[128] F. Zhou, et al., CRISPRimmunity: an interactive web server for CRISPR—associated important molecular events and modulators used in geNome edIting tool identifY—ing, Nucleic Acids Res. 51 (2023) W93-W107, doi: 10.1093/nar/gkad425.

[129] A.J. Collins, R.J. Whitaker, CRISPR comparison toolkit: rapid identification, visualization, and analysis of CRISPR array diversity, Cris. J. 6 (2023) 386-400, doi: 10.1089/crispr.2022.0080.

[130] R.C. Edgar, PILER—CR: fast and accurate identification of CRISPR repeats, BMC Bioinformat. 8 (2007) 18, doi: 10.1186/1471-2105-8-18.

[131] R. Rahmati, F. Zarimeidani, M. Reza, G. Boroujeni, S. Sadighbathi, CRISPR—assisted probiotic and In situ engineering of gut microbiota: a prospect to modification of metabolic disorders, Probiot. Antimicro. Prot. 18 (2026) 1570-1586, doi: 10.1007/s12602-025-10561-y.

[132] M.M. Elgazzar, W.M. El, Harnessing the microbiome: CRISPR—based gene editing and antimicrobial peptides in combating antibiotic resistance and cancer, Probiot. Antimicro. Prot. 17 (2025) 1938-1968, doi: 10.1007/s12602-025-10573-8.

[133] A.A. Amara, A. Shibl, Role of Probiotics in health improvement, infection control and disease treatment and management, Saudi Pharm. J. 23 (2015) 107-114, doi: 10.1016/j.jsps.2013.07.001.

[134] Y. Nazir, S.A. Hussain, A.A. Hamid, Y. Song, Probiotics and their potential preventive and therapeutic role for cancer, high serum cholesterol, and allergic and HIV diseases, Biomed Res. Int. 2018 (2018) 1-17, doi: 10.1155/2018/3428437.

[135] G. Marasco, et al., Therapeutic role of probiotics for the treatment of dyspepsia: a review of the literature, Neurogastroenterol. Motil. 37 (2025) 1-16, doi: 10.1111/nmo.70057.

[136] L. Wang, X. Cheng, L. Bai, M. Gao, and G. Kang, Positive interventional effect of engineered butyrate—producing bacteria on metabolic disorders and intestinal flora disruption in obese mice. 10 (2022) e0114721, doi: https://doi.org/10.1128/spectrum.01147-21.

[137] N. Hashemi, F. Shams, E. Sharif, M.B. Valilou, Recent advances in engineered edible probiotic vaccines: promising agents in the effectiveness of probiotics, Appl. Food Biotechnol. 11 (2024) 1-18, doi: 10.22037/afb.v11i2.46302.

[138] M. Govender, Y.E. Choonara, P. Kumar, L.C. du Toit, S. van Vuuren, V. Pillay, A review of the advancements in probiotic delivery: conventional vs. Non—conventional formulations for intestinal flora supplementation, AAPS PharmSciTech. 15 (2013) 29-43, doi: 10.1208/s12249-013-0027-1.

[139] L. Zheng, et al., CRISPR/Cas—based genome editing for Human gut commensal Bacteroides species, ACS Synth. Biol. 11 (2022) 464-472, doi: 10.1021/acssynbio.1c00543.

[140] Y. Du, Y. Liu, J. Hu, X. Peng, Z. Liu, CRISPR/Cas9 systems: delivery technologies and biomedical applications, Asian J. Pharm. Sci. 18 (2023) 100854, doi: 10.1016/j.ajps.2023.100854.

[141] Y. Wu, D. Battalapalli, M.J. Hakeem, V. Selamneni, P. Zhang, M.S. Draz, Z. Ruan, Engineered CRISPR—Cas systems for the detection and control of antibiotic—resistant infections, J. Nanobiotechn. 19 (2021) 401, doi: 10.1186/s12951-021-01132-8.

[142] A. Bearth, C.D. Otten, A.S. Cohen, Consumers’ perceptions and acceptance of genome editing in agriculture: insights from the United States of America and Switzerland, Food Res. Int. 178 (2024) 113982, doi: 10.1016/j.foodres.2024.113982.

[143] G. Busch, E. Ryan, M.A.G. von Keyserlingk, D.M. Weary, Citizen views on genome editing: effects of species and purpose, Agric. Human Val. 39 (2022) 151-164, doi: 10.1007/s10460-021-10235-9.

[144] A. Bearth, M. Siegrist, Are risk or benefit perceptions more important for public acceptance of innovative food technologies: a meta—analysis, Trends Food Sci. Technol. 49 (2016) 14-23, doi: 10.1016/j.tifs.2016.01.003.

[145] D. Giacalone, S.R. Jaeger, Consumer acceptance of novel sustainable food technologies: a multi—country survey, J. Clean. Prod. 408 (2023) 137119, doi: 10.1016/j.jclepro.2023.137119.

[146] A. Hussain, M. Ahmad, S.A. Ali, Exploring the concepts of Halal and Haram in Islam and their scientific perspective: a systematic literature review, J. Halal Ind. Serv. 7 (2024) 1-18, doi: 10.36877/jhis.a0000559.

[147] B. Bartkowski, I. Theesfeld, F. Pirscher, J. Timaeus, Snipping around for food: economic, ethical and policy implications of CRISPR/Cas genome editing, Geoforum 96 (2018) 172-180, doi: 10.1016/j.geoforum.2018.07.017.

[148] S. Wunderlich, K.A. Gatto, Consumer perception of genetically modified organisms and sources of information, Adv. Nutr. 6 (2015) 842-851, doi: 10.3945/an.115.008870.

[149] O.M. Al—Fakhrany, E. Elekhnawy, Next—generation probiotics: the upcoming biotherapeutics, Mol. Biol. Rep. 51 (2024) 505, doi: 10.1007/s11033-024-09398-5.

[150] K.S. Makarova, et al., An updated evolutionary classification of CRISPR—Cas systems including rare variants, Nat. Microbiol. 10 (2025) 3346-3361, doi: 10.1038/s41564-025-02180-8.

[151] S. Tao, H. Chen, N. Li, Y. Fang, Y. Xu, W. Liang, Association of CRISPR—Cas System with the antibiotic resistance and virulence genes in nosocomial isolates of Enterococcus, Infect. Drug Resist. 15 (2022) 6939-6949, doi: 10.2147/IDR.S388354.

[152] D. Bravo, J.M. Landete, Genetic engineering as a powerful tool to improve probiotic strains, Biotechnol. Genet. Eng. Rev. 33 (2017) 173-189, doi: 10.1080/02648725.2017.1408257.

[153] E. Basheer, et al., Engineered probiotics via synthetic biology for the treatment of metabolic diseases, J. Angiother. 6 (2022) 1-8, doi: 10.25163/angiotherapy.6210319.

[154] C. Dudeja, A. Mishra, A. Ali, P.P. Singh, A.K. Jaiswal, Microbial genome editing with CRISPR—Cas9: recent advances and emerging applications across sectors, Fermentation 11 (2025) 410, doi: 10.3390/fermentation11070410.

[155] M.G. Kim, M.J. Go, S.H. Kang, S.H. Jeong, K. Lim, Revolutionizing CRISPR technology with artificial intelligence, Exp. Mol. Med. 57 (2025) 1419-1431, doi: 10.1038/s12276-025-01462-9.

[156] P. Duhan, B. Gupta, M. Ahmed, P. Bansal, Gut microbiome engineering with probiotics: current trends and future directions, Discov. Appl. Sci. 7 (2025) 1354, doi: 10.1007/s42452-025-07622-w.

[157] T. Zhou, F. Zhao, AI—empowered human microbiome research, Gut 0 (2025) gutjnl— 2025—335946, doi: 10.1136/gutjnl-2025-335946.

[158] A. Macarrón Palacios, P. Korus, B.G.C. Wilkens, N. Heshmatpour, S.R. Patnaik, Revolutionizing in vivo therapy with CRISPR/Cas genome editing: breakthroughs, opportunities and challenges, Front. Genome. 6 (2024) 1-22, doi: 10.3389/fgeed.2024.1342193.

[159] E. Carolak, J. Czajkowska, A. Stypułkowska, W. Waszczuk, A. Dutkiewicz, K. Grzymajlo, Being a better version of yourself: genetically engineered probiotic bacteria as host defense enhancers in the control of intestinal pathogens, Gut Microbes. 17 (2025) 2519696, doi: 10.1080/19490976.2025.2519696.

[160] H.E. Romero—Luna, A. Hernández—Mendoza, A.F. González—Córdova, A. Peredo—Lovillo, Bioactive peptides produced by engineered probiotics and other food—grade bacteria: a review, Food Chem. X. 13 (2022) 100196, doi: 10.1016/j.fochx.2021.100196.

[161] N. Ali, C. Vora, A. Mathuria, N. Kataria, I. Mani, Advances in CRISPR—Cas systems for gut microbiome, Prog. Mol. Biol. Transl. Sci. 208 (2024) 59-81, doi: 10.1016/bs.pmbts.2024.07.008.

[162] U. Kumari, R. Tirkey, V. Rathi, Engineering probiotic strains for gut health enhancement using CRISPR and molecular marker—assisted technologies, Comput. Biol. Bioinforma. 14 (2026) 1-12, doi: 10.11648/j.cbb.20261401.11.

[163] J.H. Oh, J.P. van Pijkeren, CRISPR—Cas9—assisted recombineering in Lactobacillus reuteri, Nucleic Acids Res. 42 (2014) e131, doi: 10.1093/nar/gku623.

[164] A. Berlec, K. Škrlec, J. Kocjan, M. Olenic, B. Štrukelj, Single plasmid systems for inducible dual protein expression and for CRISPR—Cas9/CRISPRi gene regulation in lactic acid bacterium lactococcus lactis, Sci. Rep. 8 (2018) 1009, doi: 10.1038/s41598-018-19402-1.

[165] T.V. Plavec, A. Berlec, Engineering of lactic acid bacteria for delivery of therapeutic proteins and peptides, Appl. Microbiol. Biotechnol. 103 (2019) 2053-2066, doi: 10.1007/s00253-019-09628-y.

[166] L. Zhang, et al., Recent advances of engineered probiotics for therapeutic applications, BioDesign Res. 7 (2025) 100039, doi: 10.1016/j.bidere.2025.100039.

[167] T. Parvin, S.R. Sadras, Advanced probiotics: bioengineering and their therapeutic application, Mol. Biol. Rep. 51 (2024) 361, doi: 10.1007/s11033-024-09309-8.

[168] S. van der Els, J.K. James, M. Kleerebezem, P.A. Bron, Versatile Cas9—driven subpopulation selection toolbox for lactococcus lactis, Appl. Environ. Microbiol. 84 (2018) e02752, doi: 10.1128/AEM.02752-17.

[169] M. Rostampour, B. Panahi, R. Masoumi Jahandizi, The CRISPR—Cas system in lactiplantibacillus plantarum strains: identification and characterization using a genome mining approach, Front. Microbiol. 15 (2024) 1394756, doi: 10.3389/fmicb.2024.1394756.

[170] O. Raftopoulou, K. Malmstrom, M. Pan, R. Barrangou, Enhanced editing of bifidobacterium lactis using the endogenous type I—G CRISPR—Cas system, Appl. Environ. Microbiol. 92 (2026), doi: 10.1128/aem.01839-25.